Literature DB >> 1726010

Left ventricular hypertrophy: an independent risk factor.

F H Messerli1, R Ketelhut.   

Abstract

Left ventricular hypertrophy (LVH), an increase in the muscle mass of the left ventricle, has been identified as a powerful risk factor for future cardiovascular morbidity and mortality. The risk of acute myocardial infarction, congestive heart failure, sudden death, and other cardiovascular events increases six- to eightfold with the presence of LVH. The increase in myocardial mass lowers coronary reserve and enhances cardiac oxygen requirements, gives rise to ventricular ectopy, and impairs left ventricular filling and contractility. Hypertension, obesity, advanced age, valvular heart disease, and other disorders that cause an increase in the hemodynamic burden can lead to LVH. Left ventricular hypertrophy and its sequelae can be reduced by specific antihypertensive therapy but, despite these promising findings, future epidemiological studies are necessary to document the clinical benefits of a reduction of LVH.

Entities:  

Mesh:

Year:  1991        PMID: 1726010

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  15 in total

Review 1.  The renin-angiotensin-aldosterone system and cardiac ischaemia.

Authors:  H Ikram
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

2.  Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats.

Authors:  O Feron; S Salomone; T Godfraind
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

3.  Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats.

Authors:  W Linz; J Schaper; G Wiemer; U Albus; B A Schölkens
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

4.  Gap junction remodeling and spironolactone-dependent reverse remodeling in the hypertrophied heart.

Authors:  Jiaxiang Qu; Frank M Volpicelli; Luis I Garcia; Nefthi Sandeep; Jie Zhang; Lucrecia Márquez-Rosado; Paul D Lampe; Glenn I Fishman
Journal:  Circ Res       Date:  2008-12-18       Impact factor: 17.367

5.  Galactokinase is a novel modifier of calcineurin-induced cardiomyopathy in Drosophila.

Authors:  Teresa E Lee; Lin Yu; Matthew J Wolf; Howard A Rockman
Journal:  Genetics       Date:  2014-07-31       Impact factor: 4.562

Review 6.  Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis.

Authors:  W Linz; G Wiemer; J Schaper; R Zimmermann; K Nagasawa; P Gohlke; T Unger; B A Schölkens
Journal:  Mol Cell Biochem       Date:  1995 Jun 7-21       Impact factor: 3.396

Review 7.  Lacidipine: a review of its use in the management of hypertension.

Authors:  Paul L McCormack; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 8.  Lacidipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension.

Authors:  C R Lee; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

Review 9.  Cardiovascular magnetic resonance: Diagnostic utility and specific considerations in the pediatric population.

Authors:  Frances M Mitchell; Sanjay K Prasad; Gerald F Greil; Peter Drivas; Vassilios S Vassiliou; Claire E Raphael
Journal:  World J Clin Pediatr       Date:  2016-02-08

10.  Impact of body mass index on robot-assisted radical cystectomy.

Authors:  Zubair M Butt; Adam E Perlmutter; Pamela M Piacente; Gregory Wilding; Wei Tan; Hyung L Kim; James L Mohler; Khurshid A Guru
Journal:  JSLS       Date:  2008 Jul-Sep       Impact factor: 2.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.